PEXA AB reported a net loss of SEK 10.2 million for 2024, with declining sales and a strong focus on expanding its non-invasive lung diagnostics technology. The company faces significant funding needs and market risks but continues to advance scientific validation and global partnerships.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.